AtaiBeckley $ATAI Agrees to Eli Lilly $LLY Deal: $6.75 Cash, $2.50 CVR and Potential $3.8B Value

AtaiBeckley $ATAI soars on Eli Lilly $LLY takeover report cover

Eli Lilly and AtaiBeckley signed a definitive merger agreement. ATAI holders are entitled to $6.75 per share in cash at closing plus a non-transferable CVR worth up to $2.50 per share tied to VLS-01 Phase 3 initiation and U.S. approval plus DEA rescheduling milestones for BPL-003 and VLS-01. The transaction carries approximately $2.8 billion of upfront equity value and up to $1.0 billion of contingent value.

Biotech Radar — July 15, 2026: Biogen and Ionis — Diranersen Lowers Tau, but CELIA Leaves Clinical Risk Unresolved ($BIIB, $IONS)

Biogen Ionis

Phase 2 CELIA produced one of the most intriguing tau signals yet seen in Alzheimer’s disease, but it did not settle the key issue: why did the lowest dose show the most persuasive cognitive benefit while higher doses failed to produce a stronger response?

$BIIB · $IONS
Alzheimer’s · Tau · Antisense

Reusable Rockets Explained: The Launch Economics, $RKLB as the Worked Example, and What China’s First Booster Catch Changes

Reusable rockets launch economics explainer - $RKLB, $SPCX, China Long March 10B booster catch

A plain-English guide to the economics of reusable rockets: why refurbishing beats rebuilding, how cost-per-kg collapsed, where SpaceX ($SPCX), Blue Origin, China's Long March 10B and Rocket Lab ($RKLB) sit on the reuse ladder, a reusable triage for launch news, and what China's first booster catch does and doesn't change. Educational, not investment advice.

Biotech Radar — July 11, 2026: Chemomab, CervoMed and AtaiBeckley — $CMMB $CRVO $ATAI

Biotech

Today’s radar compares three very different catalyst structures: Chemomab’s proposed merger with Scipher Medicine and shift toward AI-guided rheumatoid arthritis development, CervoMed’s completed Phase 2a enrollment in nonfluent variant primary progressive aphasia, and AtaiBeckley’s completion of dosing in the VLS-01 Phase 2b Elumina trial ahead of a Q4 2026 topline readout.

$IONS / $AZN ATTR-CM Setback: Eplontersen Misses Phase 3 Endpoint, While $ALNY and $BBIO Gain a Cleaner Competitive Read-Through

IONS AZN

Ionis and AstraZeneca’s CARDIO-TTRansform trial did not meet its primary endpoint in transthyretin-mediated amyloid cardiomyopathy. The result does not erase Wainua’s existing polyneuropathy franchise, but it changes the near-term ATTR-CM competitive map and puts Alnylam and BridgeBio back at the center of investor attention.